4.64
+1.18(+34.10%)
Currency In USD
| Previous Close | 3.46 |
| Open | 5.78 |
| Day High | 6.77 |
| Day Low | 4.45 |
| 52-Week High | 9.97 |
| 52-Week Low | 2.48 |
| Volume | 75.07M |
| Average Volume | 3.11M |
| Market Cap | 597.02M |
| PE | -3.46 |
| EPS | -1.34 |
| Moving Average 50 Days | 4.87 |
| Moving Average 200 Days | 5.42 |
| Change | 1.18 |
If you invested $1000 in Humacyte, Inc. (HUMA) since IPO date, it would be worth $479.83 as of December 21, 2024 at a share price of $4.64. Whereas If you bought $1000 worth of Humacyte, Inc. (HUMA) shares 3 years ago, it would be worth $587.34 as of December 21, 2024 at a share price of $4.64.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
GlobeNewswire Inc.
Yesterday at 3:47 AM GMT
– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair – – In clinical testing SYMVESS was observed to have high rates of patency, or blood flow, a
Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire Inc.
Dec 02, 2024 2:05 PM GMT
DURHAM, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason,
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
GlobeNewswire Inc.
Nov 22, 2024 1:00 PM GMT
DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it will present